Amphera

Amphera is a Dutch biotech advancing MesoPher, an autologous dendritic cell therapy for solid tumors. The platform utilizes PheraLys, an off-the-shelf, allogeneic tumor lysate designed to present a broad spectrum of tumor-associated antigens to the patient's immune system. The company has reported positive Phase II results in resected pancreatic cancer, with data published in the Journal of Clinical Oncology, and is progressing into later-stage clinical development. Amphera operates as a private, pre-revenue entity spun out from Erasmus MC.

Autologous dendritic cell therapy platform loaded with PheraLys, a proprietary, off-the-shelf, allogeneic tumor cell lysate containing a broad spectrum of tumor-associated antigens (TAAs).

Amphera competes in the cancer vaccine and dendritic cell therapy segment against companies like BioNTech, Moderna (mRNA vaccines), and other cell therapy developers. Its key differentiation is the use of a standardized, allogeneic tumor lysate (PheraLys) to overcome the tumor supply bottleneck faced by fully personalized approaches.